Status:
COMPLETED
Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9
Lead Sponsor:
Laval University
Collaborating Sponsors:
Centers for Disease Control and Prevention
Conditions:
Human Papillomavirus Vaccines
Eligibility:
FEMALE
12-18 years
Phase:
PHASE3
Brief Summary
This study will assess the immunogenicity of one dose of Gardasil and one dose of Gardasil-9
Detailed Description
This is a one group exploratory study. The main objective of this study is to assess the persistance of anti-HPV after a single dose Gardasil and the effect of one dose of Gardasil-9 when administere...
Eligibility Criteria
Inclusion
- Have received a single dose of Gardasil 3-8 years before recruitement.
- \-
Exclusion
- Immunossupressed or blood coagulation problems
- \-
Key Trial Info
Start Date :
October 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 5 2016
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT03431246
Start Date
October 1 2016
End Date
December 5 2016
Last Update
February 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laval University Research Hospital Center
Québec, Canada, G1E7G9